44 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
34
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Glaxosmithkline
56
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
36
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Glaxosmithkline
24
Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline.
China Pharmaceutical University
1
KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
National Tsing Hua University
12
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Kyoto Prefectural University of Medicine
3
Quantitative analysis of histone demethylase probes using fluorescence polarization.
University of Colorado
1
A small molecule inhibitor of fungal histone acetyltransferase Rtt109.
University of Massachusetts Medical School
15
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Nagoya City University
8
Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches.
University of Oxford
51
Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase.
University of Oxford
2
Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4.
Shanghai Institute of Materia Medica
4
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
GlaxoSmithKline R&D
8
Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Osaka University
11
Phenyl-quinoline-xxo-butyric Acid Inhibitors of Histone Lysine Demethylase for the Treatment of Cancer.
Arrival Discovery
18
Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate.
University of Oxford
91
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.
University College London
17
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
44
Recent Advances with KDM4 Inhibitors and Potential Applications.
St. Jude Children'S Research Hospital
47
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
16
Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
China Pharmaceutical University
55
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Nankai University
36
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhengzhou University
7
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
5
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Kyoto Prefectural University of Medicine
6
New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.
AstraZeneca
34
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
38
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
7
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
The University of Texas M.D. Anderson Cancer Center
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.
Celgene
5
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Abbvie
7
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
16
Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A.
The University of Tokyo
10
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.
Mcgill University